China is the bigger Diabetic Retinopathy Drugs market: $868 Mn against $196 Mn in 2023, about 4.4 times as large.
India grows faster: 9% a year, against 7.5%. The gap still grows from $672 Mn to $1.3 Bn by 2033.
Clinical research: 34 active trials in China, 2 in India.
| Measure |  China |  India |
|---|---|---|
| Market size, 2023 | $868 Mn | $196 Mn |
| Market size, 2033 projected | $1.8 Bn | $465 Mn |
| Growth a year (CAGR) | 7.5% | 9% |
| Money added, 2023–2033 | $921 Mn | $269 Mn |
| Share of the world market | 8% | 1.8% |
| Size rank of 24 countries | #2 | #12 |
| Market per person, 2023 | $0.62 | $0.13 |
| Active clinical trials | 34 | 2 |
| Diabetes (adults) % of adults (WHO) | 11.2 2022 | 22.6 2022 |
| Full report | China report | India report |
Year by year, 2023 to 2033
China India · values between 2023 and 2033 are projected from the 2023 size and the CAGR.
Quick answers
Which is bigger in Diabetic Retinopathy Drugs, China or India?
China is the bigger Diabetic Retinopathy Drugs market: $868 Mn against $196 Mn in 2023, about 4.4 times as large.
Which grows faster in Diabetic Retinopathy Drugs, China or India?
India grows faster: 9% a year, against 7.5%. The gap still grows from $672 Mn to $1.3 Bn by 2033.
More Diabetic Retinopathy Drugs comparisons
Sources: market size and growth: Acuitas Health Analytics research (2023 base year, forecasts to 2033). Trials: ClinicalTrials.gov (fetched 10 Nov 2026); found by search words, so counts are a guide. Health figures: WHO. Population: World Bank.